Sponsor Dossier
Eisai
Sponsor Dossier for Eisai. ARTG portfolio, PBS-listed brands, PBAC activity, AusPAR record — compiled by arcimedes.
- Brand: ARX-LENVATINIB
- Brand: DAYVIGO
- Brand: FYCOMPA
- Brand: HALAVEN
- Brand: INOVELON
- Brand: LENVIMA
- Brand: LEQEMBI
About
Eisai is an Australian Private Company with ABN 73117970993, registered in Victoria. The company is currently active.
Portfolio
Eisai has 7 brands on the ARTG, of which 7 are indexable and 7 carry a Product Information document. 3 brands are PBS-listed, 4 have a PBAC outcome on record, and 6 have an AusPAR on record. Notable brands include ARX-LENVATINIB, DAYVIGO, FYCOMPA, HALAVEN, INOVELON, LENVIMA, LEQEMBI.
Therapeutic focus
— Neurology: 3 brands — Oncology: 3 brands — Psychiatry: 1 brand
PBS footprint
3 brands are PBS-listed, with the latest PBS schedule date 2026-10-01.
Regulatory activity
The latest PBAC outcome is 2024-07-01, across 4 brands with a PBAC outcome on record. The latest AusPAR is 2025-09-24, across 6 brands with an AusPAR on record.